Genmab — Oktober 2019

[Mcjean]

okie ty

[Mcjean]

The S curve suck's you know that;-) The curve dosent fit Genmab, we talk about a drug like insulin......most will have to take it the rest of there life. U(slang) more u treat u more on the drug. I think the non linear S-curve is too soon to develop because we will see a lot maintenance and we need to fill that cup up first maybe?

[Mcjean]

Perhaps in 2025 you will see the effect of the s-curve when the sale has reached 15bn$;-)

[E_L]

i think we may be talking about different curves lol, i was more thinking about the effect from 1st line inflows now, where they start on weekly dosing, then later to bi-weekly and then once every four weeks

[Sukkeralf]

https://endpts.com/is-there-a-recipe-for-ma-success-the-best-and-worst-buyout-deals-in-the-past-decade-offer-some-keys-to-success-and-failure/

[E_L]

as for maintenance; 2020 may be a bit too soon to see an effect of that, but for future projections i think it is waaaay undervalued

[E_L]

and nobody even talks about smoldering in their analysis

[Helge_LarsenPI-redaktør]

It amazes me that no analysts have a focus on smoldering at all.

[E_L]

it is probably a bit like solids; nobody puts any value on it, but if it fails they drop their price targets by 20%

[Sukkeralf]

The problem also is that the market does not exist yet - so hard to put numbers on - and to figure out what impact it will have on MM patients. I guess we need more data first

[Helge_LarsenPI-redaktør]

E.L. You should not joke this kind of thing here in the chat.

[Helge_LarsenPI-redaktør]

Sugaralf. You're probably right.

[bibob]

No E L. Shame on you.

[E_L]

[Bulder]

Dara for maintenance is not approved anywhere. As for smoldering, you only treat high risk pts, about 15% of pts. Limited market. Bowers value smoldering with 47 dkk.

[Bulder]

... out of 1650

[Sukkeralf]

And the problem is still that you treat people that are not sick yet - can you get reimbursement for that. And what kind of treatment would you go after - delaying the MM or a possible cure (like 4 combination therapy maybe). I think its way too early........

[E_L]

Dara isn't the full 1650... and probability weighted; if 100% approved it will get close to 3L and 4L

[Bulder]

Rather half of 3. and 4. line

[Solsen]

I belive generic Revlimid could kick in the S-curve